Literature DB >> 25332522

A Rare Presentation of Extramedullary Hematopoiesis in Post-polycythemic Myelofibrosis.

Ceyla Konca Degertekin1, Zübeyde Nur Ozkurt2, Nalan Akyürek3, Münci Yağcı2.   

Abstract

Polycythemia vera is a clonal proliferative disorder of the bone marrow that could possibly evolve into myelofibrosis in its natural course. Progression to myelofibrosis is usually a late stage complication and presents clinically with refractory cytopenias and extramedullary hematopoiesis (EMH). EMH can occur in any tissue during the course of post-polycythemic myelofibrosis. However, skin and cardiac involvements seems to be very rare. We present a 56-year-old woman with post-polycythemic myelofibrosis refractory to treatment, developing EMH after splenectomy in various organs, exceptionally the skin and the heart. Along with the case, the clinical presentations, treatment options, prognostic significance of EMH and the role of cytogenetics is discussed in the light of the literature.

Entities:  

Keywords:  Extramedullary hematopoiesis; Heart; Myelofibrosis; Polycythemia vera; Skin; Splenectomy

Year:  2012        PMID: 25332522      PMCID: PMC4192256          DOI: 10.1007/s12288-012-0218-z

Source DB:  PubMed          Journal:  Indian J Hematol Blood Transfus        ISSN: 0971-4502            Impact factor:   0.900


  41 in total

1.  EXTRAMEDULLARY MYELOID TUMORS IN PRIMARY MYELOFIBROSIS.

Authors:  P H LIEBERMAN; R V ROSVOLL; A B LEY
Journal:  Cancer       Date:  1965-06       Impact factor: 6.860

2.  Leukemic recombinations involving heterochromatin in myeloproliferative disorders with t(1;9).

Authors:  Constantina Sambani; Roberta La Starza; Valentina Pierini; Peter Vandenberghe; Juan J Gonzales-Aguilera; Helen Rigana; Daphne Koumbi; Kalliopi N Manola; Chryssa Stavropoulou; Vasileios N Georgakakos; Maria Pagoni; Iwona Wlodarska; Cristina Mecucci
Journal:  Cancer Genet Cytogenet       Date:  2005-10-01

3.  Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European Group for Blood and Marrow Transplantation, Société Française de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center Collaborative Study.

Authors:  P Guardiola; J E Anderson; G Bandini; F Cervantes; V Runde; W Arcese; A Bacigalupo; D Przepiorka; M R O'Donnell; P Polchi; A Buzyn; L Sutton; D Cazals-Hatem; G Sale; T de Witte; H J Deeg; E Gluckman
Journal:  Blood       Date:  1999-05-01       Impact factor: 22.113

4.  Presence of unfavorable cytogenetic abnormalities is the strongest predictor of poor survival in secondary myelofibrosis.

Authors:  David Dingli; Susan M Schwager; Ruben A Mesa; Chin-Yang Li; Gordon W Dewald; Ayalew Tefferi
Journal:  Cancer       Date:  2006-05-01       Impact factor: 6.860

5.  Subcutaneous extramedullary hematopoiesis in a patient with secondary myelofibrosis following polycythemia vera.

Authors:  M Tanaka; H Kanamori; S Yamaji; A Mishima; E Yamazaki; J Taguchi; M Aoba; S Fujisawa; H Mohri; Y Ishigatsubo
Journal:  Leuk Lymphoma       Date:  2001-01

Review 6.  Histochemistry and morphometry on bone marrow biopsies in chronic myeloproliferative disorders - aids to diagnosis and classification.

Authors:  J Thiele; H M Kvasnicka; R Fischer
Journal:  Ann Hematol       Date:  1999-11       Impact factor: 3.673

7.  Polycythemia vera in young patients: a study on the long-term risk of thrombosis, myelofibrosis and leukemia.

Authors:  Francesco Passamonti; Lucia Malabarba; Ester Orlandi; Claudia Baratè; Angelo Canevari; Ercole Brusamolino; Maurizio Bonfichi; Luca Arcaini; Sabrina Caberlon; Cristiana Pascutto; Mario Lazzarino
Journal:  Haematologica       Date:  2003-01       Impact factor: 9.941

8.  Fibrous hematopoietic tumors arising in agnogenic myeloid metaplasia.

Authors:  E N Beckman; J S Oehrle
Journal:  Hum Pathol       Date:  1982-09       Impact factor: 3.466

9.  Leucocytosis in polycythaemia vera predicts both inferior survival and leukaemic transformation.

Authors:  Naseema Gangat; Jacob Strand; Chin-Yang Li; Wenting Wu; Animesh Pardanani; Ayalew Tefferi
Journal:  Br J Haematol       Date:  2007-08       Impact factor: 6.998

10.  Polycythemia vera treated with -32p and myleran: development of chronic granulocytic leukemia with chromosomal abnormalities in one patient.

Authors:  P Staven; C B VAN DER Hagen; E Vogt; K Sandnes
Journal:  Clin Genet       Date:  1975-03       Impact factor: 4.438

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.